A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
NSCLC
DRUG: D-1553|DRUG: Other
Subject incidence of Dose-limiting toxicities (DLT), Subject incidence of Dose-limiting toxicities (DLT), Through out the DLT period, approximately 21 days|Number of subjects participants with adverse events, Number of subjects participants with adverse events, Till study completion, approximately 3 years|Antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation, Overall Response Rate (ORR, Complete Response \[CR\] + Partial Response \[PR\]), Till study completion, approximately 3 years
This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.